Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8WAHT)

• Drug Name: Fentanyl Drug Info
• Synonyms: fentanyl; Fentanil; Phentanyl; Fentora; Sublimaze; Fentanila; Fentanest; Duragesic; Fentanylum; Durogesic; Sentonil; 437-38-7; Duragesic-100; IONSYS; Duragesic-25; Duragesic-75; Duragesic-50; Duragesic-12; Fentanyl-25; Fentanyl-75; Fentanyl-12; Fentanyl-50; Fentanylum [INN-Latin]; Fentanila [INN-Spanish]; Fentanyl-100; 1-Phenethyl-4-N-propionylanilinopiperidine; Matrifen; Sublimase; N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide; N-(1-Phenethyl-4-piperidyl)propionanilide; N-Phenethyl-4-(N-propionylanilino)piperidine; Fentanil [DCIT]; Subsys; Fentanyl-37; Fentanyl-62; Fentanyl-87; Abstral; Actiq; Lazanda; Onsolis; Fentanyl Citrate; Fentanyl Citrate Preservative Free; Sublimaze Preservative Free; fentanyl (transmucosal film, pain), Auxilium Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Analgesia	MB40.8	Approved	[1]
Traumatic brain injury	NA07.Z	Approved	[2]
Cancer related pain	MG30	Phase 3	[3]
Pain	MG30-MG3Z	Phase 3	[4]
Chronic pain	MG30	Phase 1	[5]

• Therapeutic Class: Neurology Agents
• Cross-matching ID:
  PubChem CID: 3345
  ChEBI ID: CHEBI:119915
  CAS Number: CAS 437-38-7
  TTD Drug ID: DM8WAHT
  VARIDT Drug ID: DR00430
  INTEDE Drug ID: DR0690
  ACDINA Drug ID: D00271

Molecule-Related Drug Atlas

Drug(s) Targeting Opioid receptor mu (MOP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[17]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[18]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[19]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[20]
Alfentanil	DMVO0UB	Anaesthesia	9A78.6	Approved	[21]
Naloxegol	DML0B41	Opioid-induced constipation	DB32.1	Approved	[22]
Eluxadoline	DMYZ0P1	Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[23]
Nalfurafine hcl	DMA9DHW	Uremic pruritus	EC90.10	Approved	[24]
Oxycodone	DMXLKHV	Osteoarthritis	FA00-FA05	Approved	[25]
Methylnaltrexone bromide	DMZTGN2	Opioid-induced constipation	DB32.1	Approved	[20]

Drug(s) Transported By P-glycoprotein 1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amoxicillin	DMUYNEI	Acute otitis media	AB00	Approved	[26]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[27]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[7]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[28]
Fluorouracil	DMUM7HZ	Adenocarcinoma	2D40	Approved	[7]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[7]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[29]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[7]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[30]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[31]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[32]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[33]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[34]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[35]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[36]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[37]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[38]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[39]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[33]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[40]

Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[41]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[42]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[43]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[10]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[44]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[45]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[46]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[47]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[48]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[10]

Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[49]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[10]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[10]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[10]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[50]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[51]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[10]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[10]
Irinotecan	DMP6SC2	Adenocarcinoma	2D40	Approved	[10]
Metronidazole	DMTIVEN	Abscess		Approved	[52]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[53]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[54]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[55]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[56]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[57]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[58]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[59]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[60]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[61]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[59]

Drug(s) Affected By Mu-type opioid receptor (OPRM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alvimopan	DMHR8KW	Gastrointestinal disease	DE2Z	Approved	[62]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[63]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[65]
Butorphanol	DM5KYPJ	Pain	MG30-MG3Z	Approved	[66]
Oliceridine	DM6MDCF	Acute pain	MG31	Approved	[15]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[67]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[68]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[69]
Tianeptine	DMYN8MA	Major depressive disorder	6A70.3	Approved	[66]

Drug(s) Affected By Phospholipase D2 (PLD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[70]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[70]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[71]
Methadone	DMTW6IU	Advanced cancer	2A00-2F9Z	Approved	[14]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[72]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[72]
PMID28460551-Compound-2	DM4DOUB	N. A.	N. A.	Patented	[73]

Drug(s) Affected By Pro-opiomelanocortin (POMC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[74]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[75]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[76]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[77]
Cyproheptadine	DM92AH3	Allergic rhinitis	CA08.0	Approved	[78]
Triamcinolone	DM98IXF	Acute adrenal insufficiency		Approved	[79]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[80]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[81]
Metyrapone	DMI7FVQ	Cushing disease	5A70	Approved	[82]
Melatonin	DMKWFBT	Depression	6A70-6A7Z	Approved	[83]

Drug(s) Affected By Interleukin-4 (IL4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[84]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[85]
Tolnaftate	DM28MU7	Dermatophytosis	1F28.2	Approved	[86]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[87]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[88]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[89]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[90]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[91]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[92]
Cladribine	DM3JDRP	Hairy cell leukaemia	2A82.2	Approved	[93]

Drug(s) Affected By NF-kappa-B inhibitor alpha (NFKBIA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fructose	DM43AN2	Vomiting	MD90	Approved	[11]
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[94]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[95]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[96]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[97]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[98]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[99]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[100]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[101]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[102]

Drug(s) Affected By Mitogen-activated protein kinase 3 (MAPK3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[103]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[104]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[105]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[106]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[107]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[108]
Secobarbital	DM14RF5	Epilepsy	8A60-8A68	Approved	[109]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[110]
Fexofenadine	DM17ONX	Allergic rhinitis	CA08.0	Approved	[111]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[112]

Drug(s) Affected By Mitogen-activated protein kinase 1 (MAPK1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[113]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[104]
Carvedilol	DMHTEAO	Chronic heart failure	BD1Z	Approved	[114]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[115]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[116]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[103]
Urokinase	DM0GOUD	Myocardial infarction	BA41-BA43	Approved	[11]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[95]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[106]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[107]

Drug(s) Affected By Beta-arrestin-2 (ARRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[117]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[118]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[68]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[119]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[120]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[121]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[122]
Methamphetamine	DMPM4SK	Anxiety		Approved	[123]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[124]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[125]

Drug(s) Affected By Interleukin-2 (IL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sirolimus	DMGW1ID	Advanced cancer	2A00-2F9Z	Approved	[11]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[85]
Ribavirin	DMEYLH9	Hepatitis C virus infection	1E51.1	Approved	[87]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[126]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[127]
Naloxone	DM3FXMA	Narcotic depression	6A7Z	Approved	[128]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[129]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[130]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[131]
Folic Acid	DMEMBJC	Colorectal carcinoma		Approved	[132]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[133]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[134]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[135]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[136]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[136]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[137]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[138]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[139]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[140]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[136]

Drug(s) Affected By Opioid growth factor receptor (OGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[141]
Selenium	DM25CGV	N. A.	N. A.	Approved	[142]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[64]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[143]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[71]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[144]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[145]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[68]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[119]
Bortezomib	DMNO38U	Leukemia		Approved	[146]

Drug(s) Affected By Adenylate cyclase type 1 (ADCY1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Reserpine	DM6VM38	Hypertension	BA00-BA04	Approved	[11]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[147]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[117]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[148]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[148]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[149]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[148]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[148]
Diethylstilbestrol	DMN3UXQ	Gonorrheal vaginitis	GA02	Approved	[150]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[151]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Modulator	[6]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 3A5 (CYP3A5) Main DME	DEIBDNY	CP3A5_HUMAN	Substrate	[9]
Cytochrome P450 3A7 (CYP3A7) Main DME	DERD86B	CP3A7_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Adenylate cyclase type 1 (ADCY1)	OTSLLFZO	ADCY1_HUMAN	Drug Response	[11]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Regulation of Drug Effects	[12]
Beta-arrestin-2 (ARRB2)	OTAEJZCI	ARRB2_HUMAN	Protein Interaction/Cellular Processes	[13]
Interleukin-2 (IL2)	OTGI4NSA	IL2_HUMAN	Gene/Protein Processing	[14]
Interleukin-4 (IL4)	OTOXBWAU	IL4_HUMAN	Gene/Protein Processing	[14]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Post-Translational Modifications	[14]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Post-Translational Modifications	[14]
Mu-type opioid receptor (OPRM1)	OT16AAT8	OPRM_HUMAN	Post-Translational Modifications	[15]
NF-kappa-B inhibitor alpha (NFKBIA)	OTFT924M	IKBA_HUMAN	Gene/Protein Processing	[16]
Opioid growth factor receptor (OGFR)	OTROS6RJ	OGFR_HUMAN	Drug Response	[11]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Fentanyl FDA Label
• [3] ClinicalTrials.gov (NCT00822614) Safety of Fentanyl TAIFUN Treatment. U.S. National Institutes of Health.
• [4] A Phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic nonmalignant pain. Curr Med Res Opin. 2006 Aug;22(8):1493-501.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [7] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [8] Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther. 1999 Oct;291(1):424-33.
• [9] Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8.
• [10] Drug Interactions Flockhart Table
• [11] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [12] P-Glycoprotein on Blood-Brain Barrier Plays a Vital Role in Fentanyl Brain Exposure and Respiratory Toxicity in Rats. Toxicol Sci. 2018 Jul 1;164(1):353-362. doi: 10.1093/toxsci/kfy093.
• [13] Functional and structural characterization of axonal opioid receptors as targets for analgesia. Mol Pain. 2016 Mar 1;12:1744806916628734. doi: 10.1177/1744806916628734. Print 2016.
• [14] opioid receptor agonist-selective regulation of interleukin-4 in T lymphocytes. J Neuroimmunol. 2013 Oct 15;263(1-2):35-42. doi: 10.1016/j.jneuroim.2013.07.012. Epub 2013 Jul 25.
• [15] A G protein-biased ligand at the ?-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17.
• [16] Mechanisms of the inhibition of nuclear factor-B by morphine in neuronal cells. Mol Pharmacol. 2012 Apr;81(4):587-97. doi: 10.1124/mol.111.076620. Epub 2012 Jan 18.
• [17] Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization. J Neurosci. 2009 Jun 3;29(22):7341-8.
• [18] Antianalgesia: stereoselective action of dextro-morphine over levo-morphine on glia in the mouse spinal cord.J Pharmacol Exp Ther.2005 Sep;314(3):1101-8.
• [19] Clinical pipeline report, company report or official report of signaturerx.
• [20] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [21] Concentration-effect relationship of intravenous alfentanil and ketamine on peripheral neurosensory thresholds, allodynia and hyperalgesia of neuropathic pain. Pain. 2001 Mar;91(1-2):177-87.
• [22] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [23] Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.Biochem Pharmacol.2014 Dec 1;92(3):448-56.
• [24] Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4.
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 319).
• [26] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [27] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [28] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [29] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [30] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [31] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [32] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [33] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [34] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [35] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [36] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [37] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [38] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [39] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [40] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [41] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [42] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [43] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [44] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [45] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [46] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [47] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [48] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [49] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [50] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [51] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [52] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [53] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [54] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [55] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [56] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [57] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [58] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [59] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [60] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [61] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
• [62] The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone. Naunyn Schmiedebergs Arch Pharmacol. 2007 May;375(3):205-20. doi: 10.1007/s00210-007-0146-x. Epub 2007 Mar 6.
• [63] Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther. 2008 Apr;83(4):559-66.
• [64] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [65] The effect of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK-N-SH neuroblastoma cell. J Ethnopharmacol. 2013 Jun 21;148(1):135-43. doi: 10.1016/j.jep.2013.03.078. Epub 2013 Apr 19.
• [66] In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances. Arch Toxicol. 2020 Nov;94(11):3819-3830. doi: 10.1007/s00204-020-02855-7. Epub 2020 Jul 31.
• [67] Cannabinoid receptor type 2 agonists induce transcription of the mu-opioid receptor gene in Jurkat T cells. Mol Pharmacol. 2006 Apr;69(4):1486-91. doi: 10.1124/mol.105.018325. Epub 2006 Jan 24.
• [68] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [69] Regulation of opioid and cannabinoid receptor genes in human neuroblastoma and T cells by the epigenetic modifiers trichostatin A and 5-aza-2'-deoxycytidine. Neuroimmunomodulation. 2012;19(3):180-6. doi: 10.1159/000331474. Epub 2012 Jan 18.
• [70] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [71] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [72] Effects of tobacco compounds on gene expression in fetal lung fibroblasts. Environ Toxicol. 2008 Aug;23(4):423-34.
• [73] Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
• [74] Neuroendocrine effects of citalopram, a selective serotonin re-uptake inhibitor, during lifespan in humans. J Endocrinol Invest. 2010 Oct;33(9):657-62. doi: 10.1007/BF03346666. Epub 2010 Apr 22.
• [75] Prednisone effects on neurochemistry and behavior. Preliminary findings. Arch Gen Psychiatry. 1990 Oct;47(10):963-8. doi: 10.1001/archpsyc.1990.01810220079010.
• [76] Endogenous opioids modulate the cardiovascular response to mental stress. Psychoneuroendocrinology. 1990;15(3):185-92. doi: 10.1016/0306-4530(90)90029-9.
• [77] Normalization of blood pressure and plasma concentrations of beta-endorphin and leucine-enkephalin in patients with primary hypertension after treatment with clonidine. J Cardiovasc Pharmacol. 1987;10 Suppl 12:S147-51.
• [78] [Toxicity of cyproheptadine. Side effects and accidental overdosage (author's transl)]. Monatsschr Kinderheilkd (1902). 1978 Mar;126(3):123-6.
• [79] Steroid myopathy induced by epidural triamcinolone injection. Br J Rheumatol. 1995 Apr;34(4):385-6. doi: 10.1093/rheumatology/34.4.385.
• [80] Hormonal responses to the 5-HT1A agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment. Psychoneuroendocrinology. 2010 May;35(4):481-9. doi: 10.1016/j.psyneuen.2009.08.012. Epub 2009 Sep 16.
• [81] The role of acetaldehyde in mediating effects of alcohol on expression of endogenous opioid system genes in a neuroblastoma cell line. FASEB J. 2008 Mar;22(3):662-70. doi: 10.1096/fj.07-8346com. Epub 2007 Oct 12.
• [82] Mineralocorticoid receptor function in posttraumatic stress disorder after pretreatment with metyrapone. Biol Psychiatry. 2006 Oct 1;60(7):784-7. doi: 10.1016/j.biopsych.2006.01.014. Epub 2006 Mar 29.
• [83] [Melatonin reduces cortisol response to ACTH in humans]. Rev Med Chil. 2008 Nov;136(11):1390-7. doi: 10.4067/s0034-98872008001100004.
• [84] Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells. Eur Respir J. 1999 Nov;14(5):1106-12. doi: 10.1183/09031936.99.14511069.
• [85] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [86] Anti-mycotics suppress interleukin-4 and interleukin-5 production in anti-CD3 plus anti-CD28-stimulated T cells from patients with atopic dermatitis. J Invest Dermatol. 2001 Dec;117(6):1635-46. doi: 10.1046/j.0022-202x.2001.01566.x.
• [87] Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999 Mar;30(3):376-82. doi: 10.1016/s0168-8278(99)80093-2.
• [88] Selective inhibition of interleukin-4 gene expression in human T cells by aspirin. Blood. 2001 Mar 15;97(6):1742-9. doi: 10.1182/blood.v97.6.1742.
• [89] Immune responses in autoimmune hepatitis: effect of prednisone and azathioprine treatment: case report. Int J Med Sci. 2009 Jun 30;6(4):177-83. doi: 10.7150/ijms.6.177.
• [90] Differential effects of three antibiotics on T helper cell cytokine expression. J Antimicrob Chemother. 2005 Sep;56(3):502-6. doi: 10.1093/jac/dki251. Epub 2005 Jul 8.
• [91] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [92] Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol. 2008 May 15;180(10):6988-96. doi: 10.4049/jimmunol.180.10.6988.
• [93] Paradoxical immunologic effects of 2-CdA therapy: comment on the article by Davis et al. Arthritis Rheum. 1998 Sep;41(9):1704-5. doi: 10.1002/1529-0131(199809)41:9<1704::AID-ART26>3.0.CO;2-9.
• [94] Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-B axis: Shedding new light on resistance to Aprepitant. Int J Biochem Cell Biol. 2018 Oct;103:105-114. doi: 10.1016/j.biocel.2018.08.010. Epub 2018 Aug 23.
• [95] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [96] ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
• [97] Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
• [98] Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc. J Neurochem. 2006 Oct;99(2):402-15. doi: 10.1111/j.1471-4159.2006.04005.x.
• [99] Protein phosphatase 2A interacts with and directly dephosphorylates RelA. J Biol Chem. 2001 Dec 21;276(51):47828-33. doi: 10.1074/jbc.M106103200. Epub 2001 Oct 8.
• [100] Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
• [101] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [102] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [103] Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
• [104] Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
• [105] Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
• [106] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [107] Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
• [108] Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
• [109] Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
• [110] Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
• [111] Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
• [112] SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
• [113] Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
• [114] A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
• [115] The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
• [116] Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
• [117] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [118] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [119] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [120] Regulation of beta-adrenergic receptor signaling by S-nitrosylation of G-protein-coupled receptor kinase 2. Cell. 2007 May 4;129(3):511-22. doi: 10.1016/j.cell.2007.02.046.
• [121] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [122] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [123] Possible association of beta-arrestin 2 gene with methamphetamine use disorder, but not schizophrenia. Genes Brain Behav. 2007 Feb;6(1):107-12. doi: 10.1111/j.1601-183X.2006.00237.x.
• [124] Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 2005;5(5):324-36. doi: 10.1038/sj.tpj.6500327.
• [125] Beta-arrestin 2 modulates resveratrol-induced apoptosis and regulation of Akt/GSK3? pathways. Biochim Biophys Acta. 2010 Sep;1800(9):912-8. doi: 10.1016/j.bbagen.2010.04.015. Epub 2010 May 7.
• [126] Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4. Am J Gastroenterol. 1992 Apr;87(4):465-70.
• [127] Involvement of C3435T and G2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone. Eur J Pharmacol. 2005 Dec 28;528(1-3):27-36. doi: 10.1016/j.ejphar.2005.10.068.
• [128] Interleukin-2-induced antinociception in morphine-insensitive rats. Acta Pharmacol Sin. 2002 Nov;23(11):981-4.
• [129] Direct and indirect effects of retinoic acid on human Th2 cytokine and chemokine expression by human T lymphocytes. BMC Immunol. 2006 Nov 21;7:27. doi: 10.1186/1471-2172-7-27.
• [130] Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol. 2002 Dec;133(1-2):124-31. doi: 10.1016/s0165-5728(02)00370-3.
• [131] 1,25-Dihydroxyvitamin D3-regulated expression of genes involved in human T-lymphocyte proliferation and differentiation. Cancer Res. 1986 Nov;46(11):5827-31.
• [132] In vitro folate deficiency induces apoptosis by a p53, Fas (Apo-1, CD95) independent, bcl-2 related mechanism in phytohaemagglutinin-stimulated human peripheral blood lymphocytes. Br J Nutr. 2006 May;95(5):870-8. doi: 10.1079/bjn20051579.
• [133] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [134] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [135] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [136] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [137] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [138] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [139] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [140] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.
• [141] Cannabidiol Activates Neuronal Precursor Genes in Human Gingival Mesenchymal Stromal Cells. J Cell Biochem. 2017 Jun;118(6):1531-1546. doi: 10.1002/jcb.25815. Epub 2016 Dec 29.
• [142] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [143] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [144] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [145] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [146] The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
• [147] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [148] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [149] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [150] Analysis of gene expression induced by diethylstilbestrol (DES) in human primitive Mullerian duct cells using microarray. Cancer Lett. 2005 Apr 8;220(2):197-210.
• [151] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.